Clinical Trial Update: A Trial of Panobinostat and Trastuzumab for Adult Female Patients With HER2 Positive Metastatic Breast Cancer (MBC) Whose Disease Has Progressed on or After Trastuzumab [Phase 1, Phase 2]

View source ↗

Summary

This Clinical Trials update reports termination of a Phase 1/2 study evaluating panobinostat in combination with trastuzumab for HER2-positive metastatic breast…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Farydak (panobinostat)
• HERCEPTIN (trastuzumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Breast Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2016-05-09